Wyeth Pharmaceuticals' XYNTHA Maintains FDA Registry Standing as Recombinant Factor VIII Benchmark for Hemophilia A

For contract manufacturers and QA directors benchmarking comparability protocols for biosimilar or reformulation programs, Wyeth Pharmaceuticals' XYNTHA (Antihemophilic Factor [Recombinant], Plasma/Albumin Free; STN: BL 125264) remains an active reference point in the FDA's approved biologics registry, a status that carries direct implications for next-generation recombinant Factor VIII development.

XYNTHA holds approval for adults and children with hemophilia A across three clinical contexts: on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce bleeding frequency. The product is not indicated in patients with von Willebrand's disease, a boundary that regulatory affairs leads should note when scoping label comparisons for reformulation submissions.

The plasma/albumin-free formulation profile is the regulatory detail that carries the most weight for manufacturers currently designing or auditing manufacturing platforms for recombinant coagulation factors. As biosimilar and next-generation biologic programs advance through ICH Q10-aligned development frameworks, the absence of plasma-derived excipients in the reference product shapes the comparability exercise, particularly around extractables, process-related impurities, and sterility assurance documentation under 21 CFR Part 211.

Supporting documentation on the FDA docket includes the August 13, 2020 approval letter, clinical review, and statistical review, alongside a SOLOFUSE device-specific package insert. Regulatory leads conducting gap analyses for biosimilar dossiers should note that documents older than three years are archived separately within the FDA's approval history portal, which may affect retrieval timelines during pre-submission preparation.

The continued registry presence of XYNTHA, without modification to its approved indication set, confirms the product's standing as a stable regulatory baseline against which comparability data for recombinant Factor VIII programs will continue to be assessed.

Source: FDA Vaccines, Blood and Biologics / Approved Blood Products registry via RSS feed, July 6, 2026.